Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plague vaccine injectable - DynPort/USAMRIID

Drug Profile

Plague vaccine injectable - DynPort/USAMRIID

Alternative Names: Recombinant F1V plague vaccine - Dynport Vaccine Company; rF1V vaccine

Latest Information Update: 17 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United States Army Medical Research Institute of Infectious Diseases
  • Developer DynPort Vaccine Company
  • Class Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Yersinia infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Yersinia infections

Most Recent Events

  • 17 Mar 2017 Plague vaccine injectable is still in phase II trials for prevention of Yersinia infections in USA
  • 08 Mar 2017 Plague vaccine injectable - DynPort/USAMRIID receives Orphan Drug status for Yersinia infections in USA
  • 22 Aug 2012 DynPort completes a phase II trial in Healthy volunteers in US (NCT01122784)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top